Figure S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

• Targeting both bcl-xl and mcl-1 with bh3 mimetics significantly enhances anti-cancer effects in AR-V7-expressing CRPC models.
• Single-agent activity of bh3 mimetics was evaluated across various cell lines, including lncap95, vcap-cr, and 22rv1 cells.
• The research method involved comparative analysis of cell viability and response to drug treatment under controlled conditions.
• The findings support potential dual-targeting strategies to boost treatment efficacy against resistant prostate cancer.